¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ved Patient Model Misc"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multistage model
    ´Ù´Ü°è¸ðÇü
  • multitarget model
    ´ÙÇ¥Àû¸ðµ¨
  • multitarget multihit model
    ´ÙÇ¥Àû´ÙÀûÁ߸ðµ¨
  • multitarget single hit model
    ´ÙÇ¥Àû´ÜÀÏÀûÁ߸ðµ¨
  • organic model
    À¯±â¸ðÇü
  • plaster model
    ¼®°í¸ðÇü
  • proportional hazards model
    ºñ·ÊÀ§Çè¸ðÇü
  • psychodynamic experiential model
    Á¤½Å¿ªµ¿°æÇè¸ðÇü
  • reserve model
    ¿¹ºñ¸ðÇü
  • role model
    ¿ªÇÒÇ¥º»Çü, ¿ªÇÒ¸ðµ¨
  • social service model
    »çȸ¼­ºñ½º¸ðµ¨
  • statistical model
    Åë°è¸ðÇü
  • symmetry model
    ´ëĪÇü, ´ëμ³
  • sequential model
    ¼øÂ÷¸ðµ¨
  • single major gene locus model
    ´ÜÀÏÁÖ¿äÀ¯ÀüÀÚÀÚ¸®¸ðÇü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multitarget model
    ´ÙÇ¥Àû¸ðµ¨
  • multitarget multihit model
    ´ÙÇ¥Àû´ÙÀûÁ߸ðµ¨
  • multitarget single hit model
    ´ÙÇ¥Àû´ÜÀÏÀûÁ߸ðµ¨
  • mutiplicative model
    °ö¼À¸ðÇü
  • organic model
    À¯±â¸ðÇü
  • plaster model
    ¼®°í¸ðÇü
  • proportional hazards model
    ºñ·ÊÀ§Çè¸ðÇü
  • psychodynamic experiential model
    Á¤½Å¿ªµ¿°æÇè¸ðÇü
  • reserve model
    ¿¹ºñ¸ðÇü
  • role model
    ¿ªÇÒÇ¥º»Çü
  • sequential model
    ¼øÂ÷¸ðµ¨
  • single major gene locus model
    ´ÜÀÏÁÖ¿äÀ¯ÀüÀÚÀÚ¸®¸ðÇü
  • social service model
    m. »çȸ¼­ºñ½º¸ðµ¨
  • statistical model
    Åë°è¸ðÇü
  • symmetry model
    ´ëĪÇü, ´ëμ³
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • compartmentalization model
    ±¸È¹È­ ¸ðÇü
  • core conductor model
    ÇÙÀüµµÃ¼¸ðÇü(ú·ï³Óôô÷Ù¼úþ).
  • developmental model
    ¹ß´Þ(Û¡Ó¹)¸ðÇü
  • double helix, DNA model
  • ear model(ITE), in the
    ±Í¼ÓÇü(º¸Ã»±â)
  • fluid mosaic model
    À¯µ¿(×µÔÑ)¸ðÀÚÀÌÅ©¸ðµ¨.
  • fluid mosaic model
    À¯µ¿¼º ¸ðÀÚÀÌÅ© ¸ðµ¨
  • general linear model
    ÀϹÝÀû ¼±Çü ¸ðµ¨, ÀÏ¹Ý ¼±»ó ¸ðµ¨
  • gnathostatic model
    ¾ÇŸðÇü(¡­Ù¼úþ).
  • health belief model
    °Ç°­¹ÏÀ½ ¸ðÇü.
  • homeostatic model
    Ç×»ó¼º ¸ðÇü(Ù¼úþ)<Ç¥ÁØÇü>
  • in-the-ear model
    ±Í¼ÓÇü(º¸Ã»±â)
  • linear quadratic model
    ¼±Çü¹æÇü¸ðµ¨, ¼±ÇüÀÌÂ÷ÇÔ¼ö¸ðµ¨, LQ¸ðµ¨
  • model population
    ¸ðÇüÀα¸(ËÎÌ´ËöË´).
  • model psychosis
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • "Koshland, Nemethy, and Filmer model"
    "ÄÚ½¬·»µå,³×¸ÞƼ,ÇÊ¸Ó ¸ðµ¨"
  • leaky patch model
    ´©Ãâ(שõó) ÆäÄ¡¸ðµ¨
  • lethal mutation model
    Ä¡»çº¯ÀÌ(öÈÞÝܨì¶)¸ðµ¨
  • lipid-globular protein mosaic model
    "ÁöÁú-±¸»ó´Ü¹éÁú(ò·òõϹßÒÓ±ÛÜòõ) , ¸ðÀÚÀÌÅ©¸ðµ¨"
  • looped rolling circle model
    ·çÇÁÇü ȸÀü¿ø(üÞï®ê­)¸ðµ¨
  • master-slave model
    ÁÖÁ¾(ñ«ðô) ¸ðµ¨
  • mobile receptor model
    À̵¿¼ö¿ëü(ì¹ÔÑáôé»ô÷) ¸ðµ¨
  • model
    ¸ðµ¨
  • model system
    ¸ðµ¨½Ã½ºÅÛ
  • "Monod, Wyman, and Changeux model"
    ¸ð³ë.¿ÍÀ̸¸.¼§Á¶¸ðµ¨
  • MWC model
    "(å²) Monod, Wyman and Changeux ¸ðµ¨"
  • nearest-neighbor cooperative model
    ÃÖ±ÙÁ¢ Çùµ¿(õÌÐÎïÈúðÔÒ) ¸ðµ¨
  • nearest-neighbor exclusion model
    ÃÖ±ÙÁ¢ ¹èÁ¦(õÌÐÎïÈÛÉð¶) ¸ðµ¨
  • opposing rolling circle model
    ¿ªÈ¸Àü ¿øÇü(æ½üÞï®ê­û¡) ¸ðµ¨
  • Rabin model
    ¶óºó ¸ðµ¨
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CPK cell population kinetic [model]; creatine phosphokinase
GHPM general health policy model
GLIM generalized linear interactive model
GLM general linear model
HBM health belief model; hypertonic buffered medium
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
POHEM POpulation HEalth Model
TTM The Transtheoretical Model
UKM Urea kinetic model
MAIDS model of AIDS
APG Ambulatory Patient Groups
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • out-patient general anesthesia
    ¿Ü·¡ Àü½Å ¸¶Ãë
  • patient
    ȯÀÚ
    1. ÀÇÇÐÀû Ä¡·á¸¦ ¹Þ°í ÀÖ´Â »ç¶÷, ƯÈ÷ º´¿ø¿¡¼­. 2. ÀÇ»ç, Ä¡°ú ÀÇ»ç µî¿¡ µî·ÏµÇ¾î Çʿ信 µû¶ó ±×¿¡°Ô Ä¡·á¸¦ ¹Þ´Â »ç¶÷.
  • patient charting
    ȯÀÚ Ã­Æ® ÀÛ¼º
    ȯÀÚÀÇ Áø´Ü ¹× Ä¡·á¿¡ ÇÊ¿äÇÑ ÀûÀýÇÑ Á¤º¸¸¦ ±â·Ï, ÀÛ¼ºÇÏ´Â °Í.
  • patient coping style
    ȯÀÚÀÇ ´ëó ¾ç½Ä
  • patient exposure
    ȯÀÚ ³ëÃâ
  • patient identification
    ȯÀÚ È®ÀÎ
  • patient protection
    ȯÀÚ ¹æ¾î
  • patient's compliance
    ȯÀÚÀÇ ÀûÀÀ
  • patient's expectation
    ȯÀÚÀÇ ±â´ë
  • patient's perception
    ȯÀÚÀÇ ÀÎÁö
  • postoperative patient
    ¼ö¼úÈÄ È¯ÀÚ, ¼úÈÄ È¯ÀÚ
  • private patient
    °³ÀÎÀû ȯÀÚ, »çºñ ȯÀÚ
  • progressive patient care
    ´Ü°èÀû ȯÀÚ °ü¸®
  • specific dentist-patient relationship
    µ¶Æ¯ÇÑ Ä¡°ú ÀÇ»ç-ȯÀÚ °ü°è
  • The Interactive Microcomputer Patient Assessment Tool for Health
    ÄÄÇ»Å͸¦ ÀÌ¿ëÇÑ °Ç°­Æò°¡ ÇÁ·Î±×·¥
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
progressive patient care Organization of medical and nursing care according to the degree of illness and care requirements in the hospital. The elements are intensive care, intermediate care, self-care, long-term care, and organised home care.
(12 Dec 1998)
hospital-patient relations Interactions between hospital staff or administrators and patients. Includes guest relations programs designed to improve the image of the hospital and attract patients.
(12 Dec 1998)
nurse-patient relations Interaction between the patient and nurse.
(12 Dec 1998)
dentist-patient relations The psychological relations between the dentist and patient.
(12 Dec 1998)
diabetic patient Diabetes mellitus is a disorder that is caused by the insufficient production of the pancreatic hormone insulin. Without insulin cells are unable to absorb glucose, necessary for cellular metabolism and energy production. Patients may have type I diabetes (juvenile onset) or type II diabetes (adult onset). Individuals with either condition are considered to be diabetic.
(27 Sep 1997)
disease transmission, patient-to-professional The transmission of infectious disease or pathogens from patients to health professionals or health care workers. It includes transmission via direct or indirect exposure to bacterial, fungal, parasitic, or viral agents.
(12 Dec 1998)
disease transmission, professional-to-patient The transmission of infectious disease or pathogens from health professional or health care worker to patients. It includes transmission via direct or indirect exposure to bacterial, fungal, parasitic, or viral agents.
(12 Dec 1998)
target patient In group therapy, the patient being analyzed in turn by another member patient.
(05 Mar 2000)
unstable patient The distinction of stability is made by a physician and based on a large number of variables: patient diagnosis, vital signs, physical findings, laboratory findings, subjective factors and patient prognosis.
(27 Sep 1997)
Adair-Koshland-Nemethy-Filmer model <biochemistry, chemistry> A model to explain the allosteric form of cooperativity; in this model, in the absence of ligands, the protein exists in only one conformation; upon binding, the ligand induces a conformational change that may be transmitted to other subunits.
Synonym: Adair-Koshland-Nemethy-Filmer model, induced fit model.
(05 Mar 2000)
additive model A model in which the combined effect of several factors is the sum of the effects that would be produced by each of the factors in the absence of the others.
(05 Mar 2000)
age-structured model <epidemiology> A mathematical model which take into consideration the division of the host population into different age classes. Such models can used to consider the consequences of such factors as age-dependent infection, morbidity or mortality rates or of age-specific vaccination schedules.
(05 Dec 1998)
animal model Study in a population of laboratory animals that uses conditions of animals analogous to conditions of humans to simulate processes comparable to those that occur in human populations.
(05 Mar 2000)
Bingham model A model representing the flow behaviour of a Bingham plastic, in the idealised case.
(05 Mar 2000)
biomedical model A conceptual model of illness that excludes psychological and social factors and includes only biological factors in an attempt to understand a person's medical illness or disorder.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á